No Data
No Data
Buy Rating Affirmed for Petros Pharmaceuticals Amidst Promising Web App Technology and Strategic Advancements
Express News | Petros Pharmaceuticals' Stendra(R) (Avanafil) Pivotal Consumer Self-Selection Study for Over--Counter Access Demonstrates Statistical Significance
Petros Pharmaceuticals' STENDRA(R) (Avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Vital study aligned with FDA guidelines shows encouraging performance as Petros continues close FDA contact for a potential technology-centered Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / July 16, 2024 / Petros
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says
Petros Pharmaceuticals Inc (NASDAQ:PTPI) is a pharmaceutical company focusing on men's health therapeutics.In an interview with Benzinga, Fady Boctor, the President and Chief Commercial Officer of Pet
Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Shares of Broadcom Inc. (NASDAQ:AVGO) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for its second quarter.The company declared a quarterly dividen
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersLongeveron (NASDAQ:LGVN) stock rose 30.9% to $2.37 during Thursday's pre-market session. The company's market cap stands at $15.0 million. JanOne (NASDAQ:JAN) stock rose 26.07% to $3.24. The co
No Data